#BridgeBio Pharma (BBIO)

BridgeBio Pharma in the NEWS On March 11, 2026, BridgeBio Pharma ( BBIO ) presented additional positive data from the interim analysis of FORTIFY, the Phase 3 clinical trial of oral BBP-418, in indivi...

BridgeBio Pharma BridgeBio Pharma, Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic dis...

BridgeBio Pharma Today, March 24, 2025, BridgeBio Pharma, Inc. ( BBIO )  announced that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 s...

BridgeBio Pharma in the NEWS BridgeBio Pharma ( BBIO ) focused on genetic diseases, announced that the United States FDA approved Attruby™ (acoramidis), an orally administered near-complete stabilizer...

BridgeBio Pharma Granted Fast Track Designation for Encaleret BridgeBio Pharma ( BBIO ) announced the U.S. FDA granted Fast Track designation for Encaleret – a treatment of autosomal dominant hypocalc...